ocular hypotensive agent
Lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Acts as a prostaglandin analogues that decreases intraocular pressure by ↑ uveoscleral outflow.
↓ intraocular pressure.
Absorption: Absorbed through cornea and is converted to the active metabolite tafluprost acid.
Metabolism and Excretion: Further metabolized and eliminated.
TIME/ACTION PROFILE (↓ in intraocular pressure)
|Ophth||within 2–4 hr||12 hr||24 hr|
- Pedi: Avoid use in children due to unknown safety of chronic ↑ pigmentation.
Use Cautiously in:
- Aphakia, pseudoaphakia with a torn posterior lens capsule
- Known risk factors for macular edema
- OB: Women with child-bearing potential should practice adequate contraception
- Lactation: Use cautiously in nursing women.
Adverse Reactions/Side Effects
EENT: conjunctival hyperemia, blurred vision, cataract, permanent iris pigmentation, eyelid pigmentation, lash pigmentation/increased thickness/↑ number, macular edema, ocular stinging/irritation
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Ophth: (Adults): One drop once daily (into conjunctival sac) in the evening into affected eye(s).
Ophthalmic solution : 0.0015% in 0.3 mL single-use containers
- Measure intraocular pressure periodically during therapy.
- Readiness for enhanced knowledge, related to medication regimen (Patient/Family/Teaching)
Wash hands prior to instillation. Pull lower lid downward and look up. Instill 1 drop in conjunctival sac each evening. Each unit is for one-time use; discard after using. Store unopened foil pouches in refrigerator. Do not open pouch until ready to use.
- If used with other ophthalmic medications, administer at least 5 min apart.
- Instruct patient to use drops as directed. Do not use more than 1 drop daily; may increase intraocular pressure. Do not use for a condition for which it was not prescribed. Do not share with others, even if they have the same symptoms; may cause harm.
- Advise patient to read the Patient Information Leaflet prior to initiating therapy and with each Rx refill in case of changes.
- Inform patient of potential side effects including brownish color of the iris; may be permanent. Also, darkening of the eyelid, increasing length, thickness, color, or number of eyelashes, and hair growth on eyelids; usually reversible.
- Advise patient to notify health care professional if eye injury, eye infection, sudden loss of vision, eye surgery, swelling and redness around eye, or problems with eyelids occur.
- Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
- Advise female patient use adequate contraception during therapy and to notify health care professional if pregnancy is planned or suspected, or if breastfeeding.
Reduction of intraocular pressure.